Can a targeted antibody tame kidney inflammation without heavy steroids?
NCT ID NCT07746180
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll 20 participants who will receive the drug intravenously along with oral steroids that are quickly tapered off. The main goal is to see how many achieve complete remission, meaning no signs of active disease and no need for steroids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Obinutuzumab beta (MIL62) combined with a rapid-tapering oral glucocorticoid regimen
- What this could lead to
- If successful, this combination could offer a new treatment option for ANCA-associated glomerulonephritis, potentially achieving remission with less steroid exposure and fewer side effects.
- What could go wrong
- This is a small, early-phase exploratory study, so results may not be conclusive or generalizable. The treatment may not be effective or could cause serious side effects, including infections or infusion reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New mRNA injection aims to tame autoimmune diseases
- Engineered immune cells take on lupus and scleroderma in early trial
- Can early rituximab stop vasculitis relapses? new study aims to find out
- Experimental cell infusion aims to tame childhood autoimmune diseases
- Immune reset: CAR-T therapy targets lupus, MS, and more
- Experimental CAR t therapy targets lupus and related diseases – but trial ends early